CStone Pharmaceuticals-B (02616) Surges Over 6% in Intraday Trading as GIC Further Increases Stake, Ownership Exceeds 8%

Stock News01-07

CStone Pharmaceuticals-B (02616) saw its shares rise more than 6% during intraday trading. As of the time of writing, the stock was up 6.36%, trading at HK$5.69 with a turnover of HK$39.4446 million. According to data from the Hong Kong Stock Exchange, on December 23, 2025, Singapore's GIC increased its stake in CStone Pharmaceuticals by 904,500 shares, with a total investment of approximately HK$5.2892 million. Following this purchase, GIC's total shareholding has risen to about 119 million shares, representing an ownership stake of 8.06%. It is noteworthy that since GIC first disclosed a 5.49% stake in CStone Pharmaceuticals on August 18, 2025, its buying activity has been continuous: after two additional disclosures of stake increases on October 13 and November 10, its ownership ratio climbed to 7.11%, and has now reached 8.06% with this latest filing. A Ping An Securities research report points out that CStone Pharmaceuticals uses clinical development as its engine, with commercialized products from its R&D 1.0 phase providing reliable cash flow, while its R&D 2.0 phase projects focus on innovative pipeline layout and cutting-edge technologies; its core product candidates have already entered the clinical trial stage and the company will continue to advance further candidates into clinical development, with revenue forecasts of RMB 195 million, RMB 464 million, and RMB 633 million for 2025-2027, and the report initiates coverage with a "Recommended" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177489855?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 15:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177489855","market":"sh","top_or_hot":-1,"title":"CStone Pharmaceuticals-B (02616) Surges Over 6% in Intraday Trading as GIC Further Increases Stake, Ownership Exceeds 8%","media":"Stock News","content":"<p>CStone Pharmaceuticals-B (02616) saw its shares rise more than 6% during intraday trading. As of the time of writing, the stock was up 6.36%, trading at HK$5.69 with a turnover of HK$39.4446 million.\nAccording to data from the Hong Kong Stock Exchange, on December 23, 2025, Singapore's GIC increased its stake in CStone Pharmaceuticals by 904,500 shares, with a total investment of approximately HK$5.2892 million.\nFollowing this purchase, GIC's total shareholding has risen to about 119 million shares, representing an ownership stake of 8.06%.\nIt is noteworthy that since GIC first disclosed a 5.49% stake in CStone Pharmaceuticals on August 18, 2025, its buying activity has been continuous: after two additional disclosures of stake increases on October 13 and November 10, its ownership ratio climbed to 7.11%, and has now reached 8.06% with this latest filing.\nA Ping An Securities research report points out that CStone Pharmaceuticals uses clinical development as its engine, with commercialized products from its R&D 1.0 phase providing reliable cash flow, while its R&D 2.0 phase projects focus on innovative pipeline layout and cutting-edge technologies; its core product candidates have already entered the clinical trial stage and the company will continue to advance further candidates into clinical development, with revenue forecasts of RMB 195 million, RMB 464 million, and RMB 633 million for 2025-2027, and the report initiates coverage with a \"Recommended\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharmaceuticals-B (02616) Surges Over 6% in Intraday Trading as GIC Further Increases Stake, Ownership Exceeds 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharmaceuticals-B (02616) Surges Over 6% in Intraday Trading as GIC Further Increases Stake, Ownership Exceeds 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-07 15:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharmaceuticals-B (02616) saw its shares rise more than 6% during intraday trading. As of the time of writing, the stock was up 6.36%, trading at HK$5.69 with a turnover of HK$39.4446 million.\nAccording to data from the Hong Kong Stock Exchange, on December 23, 2025, Singapore's GIC increased its stake in CStone Pharmaceuticals by 904,500 shares, with a total investment of approximately HK$5.2892 million.\nFollowing this purchase, GIC's total shareholding has risen to about 119 million shares, representing an ownership stake of 8.06%.\nIt is noteworthy that since GIC first disclosed a 5.49% stake in CStone Pharmaceuticals on August 18, 2025, its buying activity has been continuous: after two additional disclosures of stake increases on October 13 and November 10, its ownership ratio climbed to 7.11%, and has now reached 8.06% with this latest filing.\nA Ping An Securities research report points out that CStone Pharmaceuticals uses clinical development as its engine, with commercialized products from its R&D 1.0 phase providing reliable cash flow, while its R&D 2.0 phase projects focus on innovative pipeline layout and cutting-edge technologies; its core product candidates have already entered the clinical trial stage and the company will continue to advance further candidates into clinical development, with revenue forecasts of RMB 195 million, RMB 464 million, and RMB 633 million for 2025-2027, and the report initiates coverage with a \"Recommended\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1177489855","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177489855","pubTimestamp":1767769812,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CStone Pharmaceuticals-B (02616) saw its shares rise more than 6% during intraday trading. As of the time of writing, the stock was up 6.36%, trading at HK$5.69 with a turnover of HK$39.4446 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","GIC":"Global Industry Company","BK1574":"生物医药B类股","02616":"基石药业-B","BK4104":"贸易公司与经销商"},"translate_title":"基石药业-B(02616)盘中大涨超6%GIC再增持持股超8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GIC":1,"02616":1},"content_text":"CStone Pharmaceuticals-B (02616) saw its shares rise more than 6% during intraday trading. As of the time of writing, the stock was up 6.36%, trading at HK$5.69 with a turnover of HK$39.4446 million.\nAccording to data from the Hong Kong Stock Exchange, on December 23, 2025, Singapore's GIC increased its stake in CStone Pharmaceuticals by 904,500 shares, with a total investment of approximately HK$5.2892 million.\nFollowing this purchase, GIC's total shareholding has risen to about 119 million shares, representing an ownership stake of 8.06%.\nIt is noteworthy that since GIC first disclosed a 5.49% stake in CStone Pharmaceuticals on August 18, 2025, its buying activity has been continuous: after two additional disclosures of stake increases on October 13 and November 10, its ownership ratio climbed to 7.11%, and has now reached 8.06% with this latest filing.\nA Ping An Securities research report points out that CStone Pharmaceuticals uses clinical development as its engine, with commercialized products from its R&D 1.0 phase providing reliable cash flow, while its R&D 2.0 phase projects focus on innovative pipeline layout and cutting-edge technologies; its core product candidates have already entered the clinical trial stage and the company will continue to advance further candidates into clinical development, with revenue forecasts of RMB 195 million, RMB 464 million, and RMB 633 million for 2025-2027, and the report initiates coverage with a \"Recommended\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177489855","isCrawlerRequest":true}